Fig. 1 · Structure

Documents & Downloads

CYC116

Cat. No. A10248 CAS 693228-63-6

Aurora Kinase inhibitor

Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

CYC116 produced cellular changes consistent with Aurora kinase inhibition in C1 and KOPN8 leukemia cells. At 1 µM for 18 h, treatment reduced phospho-Aurora signal and was accompanied by PARP and caspase-7 cleavage. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AuroraA ki 8nM
AuroraB ki 9nM
VEGFR2 ki 44nM
FLT3 ki 44nM
CDK2/CyclinE ki 0.39μM
CDK9/CyclinT ki 0.48μM
p70S6K ki 0.54μM
Src ki 0.82μM
CDK4/CyclinD ki 1.09μM
LCK ki 2.8μM
CDK1/CyclinB ki >10μM
CDK7/CyclinH ki >10μM
Abl ki >10μM
Akt ki >10μM
CaMKII ki >10μM
CK2 ki >10μM
ERK2 ki >10μM
GSK-3α ki >10μM
GSK-3β ki >10μM
PKA ki >10μM
PKC ki >10μM
SAPK2A(p38α) ki >10μM
PLK1 ki >10μM

23 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 170 nM Cytotoxicity against human A2780 cells after 96 hrs by MTT assay [PMID: 20462263]
A549 IC50 0.48 μM Inhibition of Aurora kinase in human A549 cells assessed as concentration required for half-maximal inhibition of histone H3 serine-10 phosphorylation after 7 hrs immunofluorescence microscopy [PMID: 20462263]
BXPC-3 IC50 1.626 μM Cytotoxicity against human BxPC3 cells after 96 hrs by MTT assay [PMID: 20462263]
CCRF-CEM IC50 0.471 μM Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay [PMID: 20462263]
COLO 205 IC50 0.241 μM Cytotoxicity against human COLO205 cells after 96 hrs by MTT assay [PMID: 20462263]
HCT-116 IC50 0.34 μM Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay [PMID: 20462263]
HeLa IC50 0.59 μM Cytotoxicity against human HeLa cells after 96 hrs by MTT assay [PMID: 20462263]
HL-60 IC50 0.372 μM Cytotoxicity against human HL60 cells after 96 hrs by MTT assay [PMID: 20462263]
HT-29 IC50 0.725 μM Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay [PMID: 20462263]
HuP-T4 IC50 0.775 μM Cytotoxicity against human HUPT4 cells after 96 hrs by MTT assay [PMID: 20462263]
K562 IC50 1.375 μM Cytotoxicity against human K562 cells after 96 hrs by MTT assay [PMID: 20462263]
MCF7 IC50 0.599 μM Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay [PMID: 20462263]
MES-SA IC50 0.09 μM Cytotoxicity against human MESSA cells after 96 hrs by MTT assay [PMID: 20462263]
MIA PaCa-2 IC50 278 nM Cytotoxicity against human MIAPaCa2 cells after 96 hrs by MTT assay [PMID: 20462263]
MV4-11 IC50 0.034 μM Cytotoxicity against human MV4-11 cells after 96 hrs by MTT assay [PMID: 20462263]
NCI-H460 IC50 0.681 μM Cytotoxicity against human NCI-H460 cells after 96 hrs by MTT assay [PMID: 20462263]
SAOS-2 IC50 0.11 μM Cytotoxicity against human Saos2 cells after 96 hrs by MTT assay [PMID: 20462263]

17 records · Scroll to view more

In Vitro Studies

CYC116 sensitivity varied substantially among leukemia cell lines in a four-day viability assay, including weaker responses in HL-60 cells and measurable effects on normal bone-marrow stroma. In mouse mast cells, CYC116 inhibited antigen-induced degranulation (IC50 ∼1.42 µM), while calcium-mobilization bypass controls remained responsive. [1,2]

Four-day CYC116 cytotoxicity profile with normal-cell controls

Cell-based study · Fourteen leukemia cell lines (B-ALL, T-ALL, AML and APML), normal lymphocytes and bone-marrow stroma [1]

Responses varied across the cell panel; normal bone-marrow stroma was also affected within the tested range. Values below are reported IC50 ± SD, representative of three separate experiments; they are assay endpoints, not administered treatment doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
C1, SEM, B1, UOCB1, Nalm6 and KOPN8 cell viabilityIC50 ± SD C1: 0.2±0.1 µM; SEM: 0.1±0.004 µM; B1: 1±0.6 µM; UOCB1: 0.2±0.09 µM; Nalm6: 0.5±0.3 µM; KOPN8: 1±0.6 µM[1]
CEM and Molt-3 cell viabilityIC50 ± SD CEM: 0.07±0.009 µM; Molt-3: 0.07±0.02 µM[1]
Molm13, MV4-11 and TIB-202 cell viabilityIC50 ± SD Molm13: 0.4±0.2 µM; MV4-11: 0.005±0.004 µM; TIB-202: 0.6±0.05 µM[1]
NB4, HL-60 and HL-60 RA cell viabilityIC50 ± SD NB4: 3±2 µM; HL-60: 7±3 µM; HL-60 RA: 0.3±0.08 µM[1]
Normal lymphocyte and bone-marrow stromal viabilityIC50 ± SD or bound Normal lymphocytes: >10 µM; bone-marrow stroma: 5±2 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Eight concentrations spanning 1×10−6 to 10 µM
Exposure duration
4 days before viability readout
Method
Alamar blue assay or automated microscopy; comparison to DMSO-treated controls
Vehicle
DMSO; final fraction not specified
Reported limits
The table does not assign a specific readout method to each model.
Methods and source locations

Compound reported in the paper: CYC116; Compound label in the paper: CYC116

Evidence for literature CYC116 in the stated models; no Adooq-lot validation or salt-equivalence claim.

Table 2, CYC116 rows and footnote; Materials and Methods: Aurora Kinase Inhibitors; Cytotoxicity Assays

C1, SEM, B1, UOCB1, Nalm6 and KOPN8 cell viability: Four-day cytotoxicity profiling; three separate experiments, triplicate wells. — Table 2, upper CYC116 row

CEM and Molt-3 cell viability: Same four-day profiling experiment. — Table 2, upper CYC116 row

Molm13, MV4-11 and TIB-202 cell viability: Same four-day profiling experiment. — Table 2, lower CYC116 row

NB4, HL-60 and HL-60 RA cell viability: Same four-day profiling experiment. — Table 2, lower CYC116 row

Normal lymphocyte and bone-marrow stromal viability: Same four-day profiling experiment; >10 is a reported bound, not an exact value. — Table 2, lower CYC116 row, normal-cell columns

Cellular Aurora phosphorylation and apoptosis-marker readouts

Cell-based study · C1 and KOPN8 B-ALL cells [1]

The CYC116 lanes showed reduced phospho-Aurora signal and cleavage of PARP and caspase 7 relative to the corresponding DMSO control. This is qualitative cellular pathway evidence, not a purified-enzyme potency or isoform-selectivity measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phospho-Aurora signal and PARP/caspase-7 cleavageQualitative immunoblot response Reduced phospho-Aurora signal with apoptosis-marker cleavage[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
18 h
Method
Immunoblotting for total Aurora-A/B, phospho-Aurora-A/B/C, PARP and caspase 7; β-actin loading control
Vehicle
DMSO; CYC116 compared with DMSO1
Reported limits
No densitometric effect size or enzyme IC50 is reported for this experiment.
Methods and source locations

Compound reported in the paper: CYC116; Compound label in the paper: CYC116

Evidence for literature CYC116 in the stated models; no Adooq-lot validation or salt-equivalence claim.

Figure 3 and caption; Results: Aurora Kinase Inhibition By Targeted Therapeutics; Materials: Immunoblotting

Phospho-Aurora signal and PARP/caspase-7 cleavage: Representative of three separate experiments; β-actin loading control. No exact band-intensity values inferred. — Figure 3, CYC lanes versus DMSO1 in C1 and KOPN8 panels; caption

Antigen-induced mast-cell degranulation and calcium-bypass controls

Cell-based study · IgE-sensitized mouse bone-marrow-derived mast cells (BMMCs) [2]

CYC116 inhibited antigen-induced β-hexosaminidase release. The same concentration range did not inhibit degranulation elicited by ionomycin or thapsigargin, limiting the effect to the tested upstream activation context.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Antigen-induced degranulationIC50 ∼1.42 µM[2]
Ionomycin- or thapsigargin-induced degranulationQualitative negative result No inhibitory effect reported at 0.2, 1 or 5 µM CYC116[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.2, 1 and 5 µM
Exposure duration
30 min pretreatment; 15 min stimulation
Method
β-Hexosaminidase release relative to total enzyme; antigen challenge 50 ng/ml DNP-HSA. Bypass controls used ionomycin (1 µM) or thapsigargin (300 nM).
Reported limits
Drug vehicle and final solvent fraction not specified in the read methods. Figure 2B washout and Figure 2C viability are excluded from adopted claims.
Methods and source locations

Compound reported in the paper: CYC116; Compound label in the paper: CYC116

Evidence for literature CYC116 in the stated models; no Adooq-lot validation or salt-equivalence claim.

Figure 2A; Figure 5A–B; Results: Effect of CYC116 on β-hexosaminidase release; Materials: Preparation and stimulation of BMMCs; Measurement of β-Hexosaminidase release

Antigen-induced degranulation: β-Hexosaminidase release; antigen-only and unstimulated controls; PP2 comparator at 10 µM. Means ± SEM from three independent experiments in triplicate. — Figure 2A and associated Results paragraph

Ionomycin- or thapsigargin-induced degranulation: Means ± SEM from three independent experiments in triplicate; matched stimulant-only and unstimulated controls. No exact percentage values inferred. — Figure 5A–B and caption; Results: Effect of CYC116 on calcium influx-induced degranulation

In Vivo Studies

In an acute mouse systemic-anaphylaxis model, a single oral CYC116 pretreatment attenuated the early fall in rectal temperature most clearly at 100 mg/kg. Lower-dose responses differed, and the experiment does not establish efficacy for chronic allergic disease. [2]

Acute oral CYC116 in a mouse systemic-anaphylaxis model

Animal study · Five-week-old male BALB/c mice; IgE-mediated passive systemic anaphylaxis [2]

Oral CYC116 attenuated the early decline in rectal temperature most clearly at 100 mg/kg. The 10 mg/kg curve remained close to PBS control during the early nadir; the response should not be generalized to all doses. This was a prophylactic acute model, not chronic allergy treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Change in rectal temperature after systemic antigen challengeQualitative response; mean ± SEM Strongest attenuation at 100 mg/kg; n=10 per group[2]

Conditions shared by the study groups

Route
Oral
Frequency
One pretreatment
Treatment course
1 h before antigen challenge; 1 h follow-up
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CYC116 dose comparison
10, 30 or 100 mg/kg
PBS-labeled control and oral cetirizine 20 mg/kg reference groupAttenuation was most pronounced at 100 mg/kg; 10 mg/kg did not prevent the early temperature fall.[2]
CYC116 dose comparison
Model: IgE-sensitized male BALB/c mice
Reported limits: Drug formulation, randomization and blinding not specified in the read methods.
Methods and source locations

Compound reported in the paper: CYC116; Compound label in the paper: CYC116

Evidence for literature CYC116 in the stated models; no Adooq-lot validation or salt-equivalence claim.

Figure 4B and caption; Materials: Animals; Passive cutaneous anaphylaxis and passive systemic anaphylaxis; Results: Effect of CYC116 on mast cell-mediated anaphylaxis in mice

Change in rectal temperature after systemic antigen challenge: Temperature measured every 10 min for 1 h. Figure denotes significance versus PBS control; no exact degree change or numerical effect size inferred. — Figure 4B, dose-response curves and caption

CYC116 dose comparison · Figure 4B and caption; Materials: passive systemic anaphylaxis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 693228-63-6
Applications Aurora Kinase inhibitor
Formula C18H20N6OS
Molecular Weight 368.5
SMILES
CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 24 mg/mL (65.13 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Jayanthan A, Ruan Y, Truong TH, et al. Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents PloS one (2014). PMID: 25048812 DOI: 10.1371/journal.pone.0102741 Source material
  2. [2] Park YH, Kim HW, Kim HS, et al. An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells Biomolecules & therapeutics (2019). PMID: 30332888 DOI: 10.4062/biomolther.2018.148 Source material

Added to your cart

View Cart Checkout
Loading...